March 24, 2020 / 10:04 PM / 11 days ago

BRIEF-Amplia Therapeutics Says U.S. FDA Awarded Co's Faki Amp945 Orphan-Drug Designation

March 25 (Reuters) - Amplia Therapeutics Ltd:

* U.S. FDA AWARDS CO’S FOCAL ADHESION KINASE INHIBITOR (FAKI) AMP945 ORPHAN-DRUG DESIGNATION FOR PANCREATIC CANCER TREATMENT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below